HomeCompareSMGBY vs ABBV

SMGBY vs ABBV: Dividend Comparison 2026

SMGBY yields 32.58% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMGBY wins by $51.1K in total portfolio value
10 years
SMGBY
SMGBY
● Live price
32.58%
Share price
$16.97
Annual div
$5.53
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$153.4K
Annual income
$21,793.51
Full SMGBY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SMGBY vs ABBV

📍 SMGBY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMGBYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMGBY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMGBY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMGBY
Annual income on $10K today (after 15% tax)
$2,768.90/yr
After 10yr DRIP, annual income (after tax)
$18,524.48/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $2,531.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMGBY + ABBV for your $10,000?

SMGBY: 50%ABBV: 50%
100% ABBV50/50100% SMGBY
Portfolio after 10yr
$127.9K
Annual income
$23,282.63/yr
Blended yield
18.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SMGBY
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMGBY buys
0
ABBV buys
0
No recent congressional trades found for SMGBY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMGBYABBV
Forward yield32.58%3.06%
Annual dividend / share$5.53$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$153.4K$102.3K
Annual income after 10y$21,793.51$24,771.77
Total dividends collected$107.9K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SMGBY vs ABBV ($10,000, DRIP)

YearSMGBY PortfolioSMGBY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$13,958$3,257.53$11,550$430.00+$2.4KSMGBY
2$19,184$4,249.26$13,472$627.96+$5.7KSMGBY
3$25,985$5,458.28$15,906$926.08+$10.1KSMGBY
4$34,714$6,909.70$19,071$1,382.55+$15.6KSMGBY
5$45,770$8,626.87$23,302$2,095.81+$22.5KSMGBY
6$59,605$10,630.52$29,150$3,237.93+$30.5KSMGBY
7$76,715$12,938.01$37,536$5,121.41+$39.2KSMGBY
8$97,648$15,562.65$50,079$8,338.38+$47.6KSMGBY
9$122,996$18,513.19$69,753$14,065.80+$53.2KSMGBY
10$153,400$21,793.51$102,337$24,771.77+$51.1KSMGBY

SMGBY vs ABBV: Complete Analysis 2026

SMGBYStock

San Miguel Corporation engages in food and beverage, packaging, energy, fuel and oil, infrastructure, cement, and banking businesses worldwide. Its Food and Beverage segment is involved in feeds production; poultry and livestock farming; processing and selling poultry and meat products and refrigerated processed and canned meat products; milling, producing, and marketing of flour, flour mixes, bakery ingredients, butter, margarine, cheese, milk, ice cream, jelly-based snacks and desserts, oils, salad aids, biscuits, and condiments; importing and marketing of coffee and coffee-related products; and grain terminal handling. This segment also produces, markets, and sells fermented, malt-based, and non-alcoholic beverages; and hard liquor in the form of gin, Chinese wine, brandy, rum, and vodka. Its Packaging segment produces and markets packaging products, such as glass containers and molds, polyethylene terephthalate (PET) bottles and preforms, PET recycling, plastic and metal closures, corrugated cartons, woven polypropylene, kraft sacks and paperboards, pallets, flexible packaging, aluminum cans, woven products, industrial laminates, and radiant barriers; and plastic crates, floorings, films, trays, pails, and tubs. This segment also engages in the crate and plastic pallet leasing, PET bottle filling graphics design, packaging research and testing, packaging development and consultation, and contract packaging and trading activities. Its Energy segment generates, sells, retails, and distributes power. Its Fuel and Oil segment refines and markets petroleum products. Its Infrastructure segment constructs and develops infrastructure projects, such as toll roads, airports, railways, and bulk water. The company also develops, manages, and sells real estate properties; and manufactures and sells cement. The company was founded in 1890 and is headquartered in Mandaluyong City, the Philippines. San Miguel Corporation is a subsidiary of Top Frontier Investment Holdings, Inc.

Full SMGBY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SMGBY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMGBY vs SCHDSMGBY vs JEPISMGBY vs OSMGBY vs KOSMGBY vs MAINSMGBY vs JNJSMGBY vs MRKSMGBY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.